| Value | ₹0.02 Cr |
|---|
BSE filing, NSE: BIOFILCHEM. Summary written from the filing by ALFA Finder's alert engine.
Biofil Chemicals & Pharmaceuticals Ltd: key numbers
- Share price
- ₹28.68
- Market cap
- ₹46.67 Cr
- Revenue (annual)
- ₹28.40 Cr
- Net profit (annual)
- ₹2.79 Cr
- P/E (TTM)
- 96.4×Sector 45.9×
- Promoter holding
- 46.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biofil Chemicals & Pharmaceuticals Ltd
All →Biofil Chemicals & Pharmaceuticals Other Announcement
The company submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 30th September 2026, confirming compliance with depository norms.
Biofil Chemicals & Pharmaceuticals Management Change
Biofil Chemicals & Pharmaceuticals shareholders approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, despite him exceeding 75 years of age.
Biofil Chemicals & Pharmaceuticals Annual General Meeting
Biofil Chemicals and Pharmaceuticals Limited held its 41st Annual General Meeting on 23rd September 2026. Members transacted routine business, including adoption of financial statements and director re-appointments.
Biofil Chemicals & Pharmaceuticals Other Announcement
Biofil Chemicals is notifying shareholders with unregistered email addresses about how to access the Annual Report and AGM Notice, per Regulation 36(1)(b) compliance requirements.
Biofil Chemicals & Pharmaceuticals Annual Report
Biofil Chemicals and Pharmaceuticals Limited has submitted its Integrated Annual Report for FY 2025-26. The 41st Annual General Meeting is scheduled for September 23, 2026.
Biofil Chemicals & Pharmaceuticals Annual General Meeting
Biofil Chemicals and Pharmaceuticals Limited will hold its 41st Annual General Meeting on September 23, 2026. The meeting will be conducted via video conferencing.
Other debt & borrowing announcements
All →ACS Technologies Debt & Borrowing: ₹30 Cr
ACS Technologies approved a Rs. 30 Crore credit facility enhancement from HDFC Bank. Total facilities now stand at Rs. 78.74 Crore, subject to bank terms.
- Value
- ₹30.00 Cr
Edelweiss Financial Services Debt & Borrowing: ₹15.43 Cr
Edelweiss Financial Services paid Rs.15.43 Crore interest across 45 secured NCD series on 30 October 2026. Payments were made ahead of the 2 November due date.
- Value
- ₹15.43 Cr
Signatureglobal (India) Debt & Borrowing
Signatureglobal disclosed corporate guarantees issued by its wholly owned subsidiaries to IndusInd Bank facilities. The guarantees secure Rs 150 crore, Rs 250 crore and Rs 398.3 crore of term loan facilities.
LIC Housing Finance Debt & Borrowing
LIC Housing Finance reported a 1.24x security cover on listed secured NCDs. It is a Regulation 54 certificate with no new event amount.
Religare Enterprises Debt & Borrowing: ₹150 Cr
Care Health Insurance, a material subsidiary of Religare, allotted listed subordinated debentures worth ₹150 Crore at a 10.50% coupon. The debentures mature in 2036, callable after five years.
- Value
- ₹150.0 Cr
Blue Coast Hotels Debt & Borrowing: ₹14.52 Cr
Blue Coast Hotels defaulted on Rs 14.52 crore principal and dividend on redeemable preference shares. Default occurred 30 October 2026, affecting unlisted debt holders.
- Value
- ₹14.52 Cr